Portal de Periódicos da CAPES

Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland

2014; Multidisciplinary Digital Publishing Institute; Volume: 11; Issue: 3 Linguagem: Inglês

10.3390/ijerph110303032

1661-7827

Stéphane Deline, Stéphanie Baggio, Joseph Studer, Alexandra N’Goran, Marc Dupuis, Yves Henchoz, Meichun Mohler‐Kuo, Jean‐Bernard Daeppen, Gerhard Gmel,

Pharmaceutical studies and practices

The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others.Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors. A total of 5,967 participants responded to questions on six types of NDs (wakefulness medication, antidepressants, Alzheimer's disease medication, Parkinson's disease medication, attention deficit-hyperactivity disorder (ADHD) medication, and beta-blockers). The frequency of use depending on five expectations (to enhance wakefulness, attention, memory, concentration and stress reduction) was analyzed for a twelve-month period.(1) About 3% of the sample indicated use of at least one ND; (2) ADHD medication was the most prevalent; (3) The type of ND preferred differed depending on academic status (4). Quantitatively, over the year, college student users used ND much less frequently than other users.Prevalence of ND use is low in Switzerland relative to other countries such as the United States. Patterns of ND use differed depending on academic status, suggesting that while college student ND users tended to do so rarely (probably to enhance cognitive abilities for exams), non-college male users used other NDs more frequently (probably to "get high").